Physician profile
Michael Feld
NPI 1427057322
$1,059,706.39
in general payments reported to CMS, 2019-2025
16 companies · $134K in 2025
The $134K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $47K · 2021: $71K · 2022: $194K · 2023: $337K · 2024: $126K · 2025: $134K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $267K · Honoraria: $221K · Travel and Lodging: $83K · Food and Beverage: $15K · Consulting Fee: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $266,904.78 |
| Honoraria | $220,600.00 |
| Travel and Lodging | $82,944.41 |
| Food and Beverage | $15,160.68 |
| Consulting Fee | $11,470.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $326,583.19 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Corium, LLC | $214,266.85 | 2021-2025 | Azstarys, Azstarys |
| Supernus Pharmaceuticals, INC. | $200,710.81 | 2020-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $174,285.10 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, Lp | $127,347.05 | 2019-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Aytu Biopharma, INC. | $15,394.26 | 2021-2025 | |
| Lundbeck LLC | $555.53 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $324.38 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $59.60 | 2019-2021 | |
| Axsome Therapeutics, INC. | $52.61 | 2023-2025 | Auvelity |
| Arbor Pharmaceuticals, INC. | $44.75 | 2019 | |
| Noven Therapeutics, LLC | $30.17 | 2023 | Xelstrym |
| E.R. Squibb & Sons, L.L.C. | $14.83 | 2025 | Cobenfy |
| Rhodes Pharmaceuticals L.P. | $13.10 | 2019 | |
| Shire North American Group INC | $13.01 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $11.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Feld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.